Kwality Pharmaceutical Secures Bleomycin Registration in Mexico, Expands Oncology Portfolio Aug 18, 2025
Kwality Pharmaceuticals Board Approves Key Reappointments and Sets 42nd AGM Date Aug 16, 2025
More news about Kwality Pharmaceuticals
11Aug 25
Kwality Pharmaceuticals Reports Robust 39.8% Revenue Growth in Q1 FY26
Kwality Pharmaceuticals Limited announced robust Q1 FY26 financial results. Consolidated revenue increased by 39.8% to ₹111.80 crore, EBITDA grew by 39% to ₹24.60 crore, and net profit rose by 43% to ₹11.90 crore. The company successfully completed a regulatory audit in Zimbabwe and received multiple new product registrations. Kwality is preparing for EU-GMP and WHO-GMP audits, and has initiated line expansion for its first biological product, Erythropoietin. Management remains confident in achieving the ₹500.00 crore revenue target for FY26.
26Jul 25
Kwality Pharmaceuticals Reshuffles Board, Appoints New Independent Director
Kwality Pharmaceuticals has appointed Dr. Vinod Kumar Sharma as an Additional Non-Executive Independent Director for a five-year term starting July 26, 2025, subject to shareholder approval. Dr. Sharma brings over 30 years of pharmaceutical industry experience. Kiran Kumar Verma has resigned as Independent Director effective July 26, 2025. The company has also restructured its Audit Committee and Nomination and Remuneration Committee following these changes.
19May 25
Kwality Pharmaceuticals Reports Q4 EBITDA Growth and Triple-Digit Profit Surge
Kwality Pharmaceuticals has announced impressive Q4 financial results. Net profit soared 222.22% year-over-year to ₹145.00 crore, while revenue increased by 25% to ₹115.00 crore. EBITDA grew to ₹25.90 crore, though the EBITDA margin slightly decreased to 22.38%. The company's performance indicates strong market positioning and effective operational management.